{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "19399188", "DateCompleted": {"Year": "2009", "Month": "07", "Day": "13"}, "DateRevised": {"Year": "2022", "Month": "02", "Day": "25"}, "Article": {"ArticleDate": [{"Year": "2009", "Month": "04", "Day": "28"}], "Language": ["eng"], "ELocationID": ["e5365", "10.1371/journal.pone.0005365"], "Journal": {"ISSN": "1932-6203", "JournalIssue": {"Volume": "4", "Issue": "4", "PubDate": {"Year": "2009"}}, "Title": "PloS one", "ISOAbbreviation": "PLoS One"}, "ArticleTitle": "A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a potential anti-cancer agent.", "Pagination": {"StartPage": "e5365", "MedlinePgn": "e5365"}, "Abstract": {"AbstractText": ["We report here the isolation and characterization of a new compound Ailanthus excelsa chloroform extract-1 (AECHL-1) (C(29)H(36)O(10); molecular weight 543.8) from the root bark of Ailanthus excelsa Roxb. The compound possesses anti-cancer activity against a variety of cancer cell lines of different origin.", "AECHL-1 treatment for 12 to 48 hr inhibited cell proliferation and induced death in B16F10, MDA-MB-231, MCF-7, and PC3 cells with minimum growth inhibition in normal HEK 293. The antitumor effect of AECHL-1 was comparable with that of the conventional antitumor drugs paclitaxel and cisplatin. AECHL-1-induced growth inhibition was associated with S/G(2)-M arrests in MDA-MB-231, MCF-7, and PC3 cells and a G(1) arrest in B16F10 cells. We observed microtubule disruption in MCF-7 cells treated with AECHL-1 in vitro. Compared with control, subcutaneous injection of AECHL-1 to the sites of tumor of mouse melanoma B16F10 implanted in C57BL/6 mice and human breast cancer MCF-7 cells in athymic nude mice resulted in significant decrease in tumor volume. In B16F10 tumors, AECHL-1 at 50 microg/mouse/day dose for 15 days resulted in increased expression of tumor suppressor proteins P53/p21, reduction in the expression of the oncogene c-Myc, and downregulation of cyclin D1 and cdk4. Additionally, AECHL-1 treatment resulted in the phosphorylation of p53 at serine 15 in B16F10 tumors, which seems to exhibit p53-dependent growth inhibitory responses.", "The present data demonstrate the activity of a triterpenoid AECHL-1 which possess a broad spectrum of activity against cancer cells. We propose here that AECHL-1 is a futuristic anti-cancer drug whose therapeutic potential needs to be widely explored for chemotherapy against cancer."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Department, Faculty of Technology and Engineering, The MS University of Baroda, Vadodara, Gujarat, India."}], "Identifier": [], "LastName": "Lavhale", "ForeName": "Manish S", "Initials": "MS"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Kumar", "ForeName": "Santosh", "Initials": "S"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Mishra", "ForeName": "Shri Hari", "Initials": "SH"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Sitasawad", "ForeName": "Sandhya L", "Initials": "SL"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Retracted Publication"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "PLoS One", "NlmUniqueID": "101285081", "ISSNLinking": "1932-6203"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents, Phytogenic"}, {"RegistryNumber": "0", "NameOfSubstance": "Cell Cycle Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Triterpenes"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Suppressor Proteins"}, {"RegistryNumber": "P88XT4IS4D", "NameOfSubstance": "Paclitaxel"}, {"RegistryNumber": "Q20Q21Q62J", "NameOfSubstance": "Cisplatin"}], "CommentsCorrectionsList": [{"RefSource": "PLoS One. 2020 Mar 27;15(3):e0231249. doi: 10.1371/journal.pone.0231249", "PMID": "32218592"}], "MeshHeadingList": [{"QualifierName": ["chemistry"], "DescriptorName": "Ailanthus"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemistry", "isolation & purification", "pharmacology"], "DescriptorName": "Antineoplastic Agents, Phytogenic"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cell Cycle Proteins"}, {"QualifierName": [], "DescriptorName": "Cell Line"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Cisplatin"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Melanoma, Experimental"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred C57BL"}, {"QualifierName": [], "DescriptorName": "Mice, Nude"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": [], "DescriptorName": "Neoplasm Transplantation"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Paclitaxel"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Prostatic Neoplasms"}, {"QualifierName": [], "DescriptorName": "Transplantation, Heterologous"}, {"QualifierName": ["chemistry", "isolation & purification", "pharmacology"], "DescriptorName": "Triterpenes"}, {"QualifierName": ["metabolism"], "DescriptorName": "Tumor Suppressor Proteins"}], "CoiStatement": "<b>Competing Interests: </b>The authors have declared that no competing interests exist."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "American Cancer Society. Cancer Facts & Figures 2002"}, {"Citation": "Ferlay J, Bray F, Parkin DM, Pisani P, editors. Globocan 2000: Cancer Incidence and Mortality Worldwide. IARC Cancer Bases No. 5. Lyon: IARCPress; 2001."}, {"Citation": "Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. In: Elisabetsky E, Etkin NL, editors. Ethnopharmacology. In Encyclopedia of Life Support Systems (EOLSS). Developed under the Auspices of the UNESCO. Oxford, UK: Eolss Publishers; 2004."}, {"Citation": "Philip PA. Experience with docetaxel in the treatment of gastric cancer. Semin Oncol. 2005;32:24\u201338.", "ArticleIdList": ["16015552"]}, {"Citation": "Chung KT, Wong TY, Wei CI, Huang YW, Lin Y. Tannins and human health: a review. Crit Rev Food Sci Nutr. 1998;38:421\u2013424.", "ArticleIdList": ["9759559"]}, {"Citation": "Ronconi L, Giovagnini L, Marzano C, Bettio F, Graziani R, et al. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties and in vitro antitumor activity. Inorg Chem. 2005;44:1867\u20131881.", "ArticleIdList": ["15762713"]}, {"Citation": "Alderden RA, Hall MD, Hambley TW. The discovery and development of cisplatin. J Chem Ed. 2006;83:728\u2013734."}, {"Citation": "Tang W, Hemm I, Bertram B. Recent development of antitumor agents from Chinese herbal medicines; Part I. Low molecular compounds. Planta Med. 2003;69:97\u2013108.", "ArticleIdList": ["12624812"]}, {"Citation": "Dzubak P, Hajduch M, Vydra D, Hustova A, Kvasnica M, et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep. 2006;23:394\u2013411.", "ArticleIdList": ["16741586"]}, {"Citation": "Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, et al. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett. 1998;8:2711\u20132714.", "ArticleIdList": ["9873608"]}, {"Citation": "Honda T, Honda Y, Favaloro FG, Jr, Gribble GW, Suh N, et al. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett. 2002;12:1027\u20131030.", "ArticleIdList": ["11909709"]}, {"Citation": "Kirtikar KR, Basu BD. Indian Medicinal Plants. Vol. 1. Dehradun, India: International Books Distributor; 1995. pp. 505\u2013507."}, {"Citation": "Honda T, Imao K, Nakatsuka N, Nakanishi T. Novel Ailanthone Derivatives and Production Process Thereof. 1987. United States Patent No. 4665201."}, {"Citation": "Ogura M, Cordell GA, Fransworth NR. Alkaloid constituents of A. excelsa. Lloydia. 1978;41:166."}, {"Citation": "Lasek W, Wankowicz A, Kuc K, Feleszko W, Golab J, et al. Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in an MmB16 melanoma model in mice. Cancer Immunol Immunother. 1995;40:315\u2013321.", "ArticleIdList": ["7600564"]}, {"Citation": "Pallavicini MG, Gray JW, Darzynkiewicz Z, editors. Techniques in Cell Cycle Analysis. 139\u2013162. Clifton, NJ: Humana Press; 1987."}, {"Citation": "Brady H, Desai S, Gayo-Fung LM, Khammungkhune S, McKie JA, et al. Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models. Cancer Res. 2002;62:1439\u20131442.", "ArticleIdList": ["11888917"]}, {"Citation": "Ruohola JK, Viitanen TP, Valve EM, Seppanen JA, Loponen NT, et al. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res. 2001;61:4229\u20134237.", "ArticleIdList": ["11358849"]}, {"Citation": "Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, et al. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity. Cancer Res. 2006;66:951\u2013959.", "ArticleIdList": ["16424030"]}, {"Citation": "Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, et al. Distinct and complementary information provided by use of tissue and cDNA microarrays in the study of breast tumor markers. Am J Pathol. 2002;161:1223\u20131233.", "ArticleIdList": ["PMC3278769", "12368196"]}, {"Citation": "Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49\u201353.", "ArticleIdList": ["1905840"]}, {"Citation": "Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 1998;58:4023\u20134037.", "ArticleIdList": ["9751603"]}, {"Citation": "Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res. 2002;4:70\u201376.", "ArticleIdList": ["PMC138723", "11879567"]}, {"Citation": "Schneider L, Essmann F, Kletke A, Rio P, Hanenberg H, et al. TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21WAF-mediated cell cycle arrest. Oncogene. 2008;27:116\u2013125.", "ArticleIdList": ["17599038"]}, {"Citation": "Stewart ZA, Tang LJ, Pietenpol JA. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene. 2001;20:113\u2013124.", "ArticleIdList": ["11244509"]}, {"Citation": "Shouse GP, Cai X, Liu X. Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol. 2008;28:448\u2013456.", "ArticleIdList": ["PMC2223295", "17967874"]}, {"Citation": "Baruah H, Barry CG, Bierbach U. Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation. Curr Top Med Chem. 2004;4:1537\u20131549.", "ArticleIdList": ["15579095"]}, {"Citation": "Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. P21 is a universal inhibitor of cyclin kinases. Nature. 1993;366:701\u2013704.", "ArticleIdList": ["8259214"]}, {"Citation": "Yim D, Singh RP, Agarwal C, Lee S, Chi H, et al. A novel anti-cancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res. 2005;65:1035\u20131144.", "ArticleIdList": ["15705905"]}, {"Citation": "Bishop JM. Cellular oncogene and retroviruses. Annu Rev Biochem. 1983;52:301\u2013354.", "ArticleIdList": ["6351725"]}, {"Citation": "Karn J, Watson JV, Lowe AD, Green SM, Vedeckis W. Regulation of cell cycle duration by c-myc levels. Oncogene. 1989;4:773\u2013787.", "ArticleIdList": ["2660073"]}, {"Citation": "Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol. 1999;19:4672\u20134683.", "ArticleIdList": ["PMC84265", "10373516"]}]}], "History": [{"Year": "2009", "Month": "2", "Day": "3"}, {"Year": "2009", "Month": "3", "Day": "11"}, {"Year": "2009", "Month": "4", "Day": "29", "Hour": "9", "Minute": "0"}, {"Year": "2009", "Month": "4", "Day": "29", "Hour": "9", "Minute": "0"}, {"Year": "2009", "Month": "7", "Day": "14", "Hour": "9", "Minute": "0"}, {"Year": "2009", "Month": "4", "Day": "28"}], "PublicationStatus": "ppublish", "ArticleIdList": ["19399188", "PMC2671403", "10.1371/journal.pone.0005365"]}}], "PubmedBookArticle": []}